Chemotherapy as treatment of primary and recurrent small cell lung cancer (Q34384463)

1 August 2017

1 reference

title

Chemotherapy as treatment of primary and recurrent small cell lung cancer (English)

1 reference

1 August 2017

1 reference

1 reference

0 references

Schuette W

1

1 reference

1 August 2017

language of work or name

1 reference

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

33 Suppl 1

1 reference

1 August 2017

page(s)

S99-107

1 reference

Small cell lung cancer. State-of-the-art therapy 1994.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

New chemotherapy agents for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Improvement of long-term survival in extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Systemic chemotherapy of brain metastases from small-cell lung cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Topotecan--a new treatment option in the therapy of brain metastases of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Second-line chemotherapy for relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Reinduction chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900309-9

7 January 2021

10.1016/S0169-5002(01)00309-9

Identifiers

DOI

1 reference

1 August 2017

1 reference